October 26, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent
 

Tokyo, Dec 28, 2012 (JCN) - Kobe University, KNC Laboratories and Dainippon Sumitomo Pharma Co., Ltd. have announced the signing of an exclusive world-wide license agreement for the development, manufacturing and sales of promising compounds co-discovered by Kobe University and KNC, that are related to the Ras signaling pathway.

According to the agreement, DSP will make an upfront payment and thereafter milestone and royalty payments to Kobe University and KNC.

In addition, DSP and Kobe University have signed a joint research agreement aiming at the discovery of anti-cancer drugs, beyond the scope of the license agreement, that are relevant to the Ras-dependent signal transduction.

Kobe University has continually aimed to contribute to society with innovative drug discovery through many years of research at Graduate School of Medicine, and to apply its knowledge to society through licensing.

On the other hand, KNC is progressing its development of business proposals in medicinal chemistry based on its own technical capabilities in organic synthesis.

Kobe University determined the three-dimensional structure of the target protein by X-ray crystallography and NMR spectroscopy, and discovered a "druggable", specific pocket on the surface of the target protein which can be targeted by low molecular weight compounds.

Kobe University has carried out drug discovery research in collaboration with KNC using this pocket as a "keyhole", searching for "keys", i.e., compounds that are able to inhibit the functions of the protein by fitting into the pocket.

Both parties have succeeded in the design and synthesis of the compounds with good anti-cancer activities in pre-clinical studies by utilizing methods such as in silico docking simulations and structural biology studies.

By Chris Lui Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Dainippon Sumitomo News  
  Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S.  (Oct 10, 2013)
  Dainippon Sumitomo Pharma Opens Subsidiary in Singapore  (Jan 22, 2013)
  Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent  (Dec 28, 2012)
  NOTICE of establishment of Drug Discovery Consortium in neuropsychiatric area  (Oct 23, 2008)
  Dainippon Sumitomo, AstraZeneca to Develop Antiallergic Drug  (May 8, 2008)
  Dainippon Sumitomo Pharma Review of Overseas Development of Lurasidone (SM-13496), an Atypical Antipsychotic  (Dec 13, 2006)
  Dainippon Sumitomo Pharma Revises Domestic Development Plan of AC-5216, an Antianxiety/antidepressant Agent  (Nov 28, 2006)
  Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'  (Sept 21, 2006)
  Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'  (Sept 21, 2006)
  Dainippon Sumitomo Pharma Enters into Partnership Agreement on Anti-Hypertension and Hepatocellular Cancer Drugs  (July 26, 2006)



 Recent  Biotech News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Biotech news...

 Recent  Medical News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Medical news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)